M-AML组(MDS-AML、MDS/MPN-AML)与tAML组患者allo-HSCT预后相近。移植时疾病未缓解和伴有TP53突变是不良预后因素。ELN2022危险分层对继发AML患者allo-HSCT预后的预测价值有限。. This evidence concerns the gene TP53 and acute myeloid leukemia.